Published in Nat Rev Gastroenterol Hepatol on January 29, 2013
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. Gut (2014) 1.60
Kyoto global consensus report on Helicobacter pylori gastritis. Gut (2015) 1.47
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol (2014) 0.93
Brain-gut axis in the pathogenesis of Helicobacter pylori infection. World J Gastroenterol (2014) 0.90
Current status of functional dyspepsia in Korea. Korean J Intern Med (2014) 0.89
Helicobacter pylori: Helicobacter pylori gastritis-a novel distinct disease entity. Nat Rev Gastroenterol Hepatol (2015) 0.88
Impact of microscopic duodenitis on symptomatic response to Helicobacter pylori eradication in functional dyspepsia. Dig Dis Sci (2014) 0.85
Changes in serum ghrelin level in relation to meal-time in patients with functional dyspepsia. United European Gastroenterol J (2015) 0.83
Prevalence of Helicobacter pylori infection and atrophic gastritis in patients with dyspeptic symptoms in Myanmar. World J Gastroenterol (2015) 0.82
Transient receptor potential vanilloid 4 (TRPV4) silencing in Helicobacter pylori-infected human gastric epithelium. Helicobacter (2016) 0.82
Helicobacter pylori and functional dyspepsia: an unsolved issue? World J Gastroenterol (2014) 0.81
Role of Helicobacter pylori in Functional Dyspepsia: More Controversies Than Answers. J Neurogastroenterol Motil (2013) 0.78
Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol (2016) 0.77
Increase in plasma acyl ghrelin levels is associated with abatement of dyspepsia following Helicobacter pylori eradication. J Gastroenterol (2015) 0.77
Efficacy and tolerability of levosulipride, domperidone and metoclopramide in patients with non-ulcer functional dyspepsia: a comparative analysis. J Clin Diagn Res (2015) 0.76
Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J (2013) 0.76
RELATIONSHIP BETWEEN THE PRESENCE OF HELICOBACTER PYLORI WITH INFLAMMATORY ENDOSCOPIC CHANGES IN GASTRODUODENAL MUCOSA. Arq Bras Cir Dig (2016) 0.75
The Role of H. pylori CagA in Regulating Hormones of Functional Dyspepsia Patients. Gastroenterol Res Pract (2016) 0.75
Do we need to eradicate Helicobacter pylori in patients with GORD? United European Gastroenterol J (2013) 0.75
Functional relationship between Campylobacter concisus and the stomach ecosystem in health and disease. ISME J (2013) 0.75
Association of the Extent of Atrophic Gastritis With Specific Dyspeptic Symptoms. J Neurogastroenterol Motil (2015) 0.75
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol (2015) 0.75
Is Helicobacter pylori Associated Functional Dyspepsia Correlated With Dysbiosis? J Neurogastroenterol Motil (2017) 0.75
Low Yield and High Cost of Gastric and Duodenal Biopsies for Investigation of Symptoms of Abdominal Pain During Routine Esophagogastroduodenoscopy. Dig Dis Sci (2016) 0.75
Pepsinogen-II 100 bp ins/del gene polymorphism and its elevated circulating levels are associated with gastric cancer, particularly with Helicobacter pylori infection and intestinal metaplasia. Gastric Cancer (2015) 0.75
Helicobacter pylori-Associated Upper Gastrointestinal Symptoms: FD or HpD? Dig Dis Sci (2017) 0.75
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med (1998) 4.99
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
A patient questionnaire to identify bowel disease. Ann Intern Med (1989) 3.43
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med (2001) 3.28
Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology (2008) 3.25
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ (2000) 2.92
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med (2011) 2.57
Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter (2010) 2.50
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol (2011) 2.35
Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut (2000) 2.06
Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut (1993) 2.05
Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet (1992) 1.88
Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol (2011) 1.79
Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut (2001) 1.71
Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol (2012) 1.66
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol (2007) 1.57
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut (2005) 1.49
High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy (2007) 1.49
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther (2012) 1.45
Morphological and functional restoration of parietal cells in helicobacter pylori associated enlarged fold gastritis after eradication. Gut (1999) 1.44
Association between Helicobacter pylori virulence factors and gastroduodenal diseases in Okinawa, Japan. J Clin Microbiol (2011) 1.37
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther (2005) 1.34
Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol (2006) 1.21
Roles of oxidative stress in stomach disorders. J Clin Biochem Nutr (2011) 1.20
Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab (2004) 1.18
Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol (2004) 1.16
Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol (2011) 1.16
Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. Am J Gastroenterol (2005) 1.14
Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.12
Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. Gut (2004) 1.12
Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology (2010) 1.10
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (2009) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
Nodular gastritis in adults is caused by Helicobacter pylori infection. Dig Dis Sci (2003) 1.10
The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol (2010) 1.09
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08
Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischaemia and reperfusion. Neurogastroenterol Motil (2009) 1.07
Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut (1993) 1.04
Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. J Gastroenterol (2006) 1.04
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther (2001) 1.03
Functional dyspepsia: past, present, and future. J Gastroenterol (2008) 1.03
Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter (2007) 1.03
Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin. Hepatogastroenterology (2012) 1.03
Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol (2012) 1.02
Gastrin and somatostatin in Helicobacter pylori infected antral mucosa. Gut (1994) 1.00
Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil (2011) 1.00
Functional dyspepsia. Curr Opin Gastroenterol (2011) 0.98
Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol (2003) 0.98
Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull (1998) 0.98
How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology (1997) 0.97
Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol (2011) 0.96
The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol (2008) 0.96
Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology (2004) 0.95
There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther (2001) 0.95
Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol (2011) 0.95
Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther (2004) 0.95
The risks of PPI therapy. Nat Rev Gastroenterol Hepatol (2012) 0.94
What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? J Neurogastroenterol Motil (2011) 0.94
Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull (2011) 0.94
H. pylori-Eradication Therapy Increases RUNX3 Expression in the Glandular Epithelial Cells in Enlarged-Fold Gastritis. J Clin Biochem Nutr (2010) 0.93
Nodular gastritis in adults: clinical features, endoscopic appearance, histopathological features, and response to therapy. J Gastroenterol Hepatol (2007) 0.93
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio J Med (2003) 0.92
Ghrelin: new molecular pathways modulating appetite and adiposity. Obes Facts (2010) 0.92
WITHDRAWN: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev (2011) 0.91
The effect of helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther (1999) 0.91
[Guidelines for the treatment of functional dyspepsia]. Korean J Gastroenterol (2011) 0.90
Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther (2003) 0.89
The association between antral G and D cells and mucosal inflammation, atrophy, and Helicobacter pylori infection in subjects with normal mucosa, chronic gastritis, and duodenal ulcer. Am J Gastroenterol (1998) 0.88
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil (2008) 0.88
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol (2012) 0.87
Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol (2011) 0.87
Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol (2010) 0.87
Relation between histologic gastritis and gastric motility in Japanese patients with functional dyspepsia: evaluation by transabdominal ultrasonography. J Gastroenterol (2008) 0.87
The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by 13C-urea breath test and associated factors. Aliment Pharmacol Ther (2001) 0.86
Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of Helicobacter pylori-negative normal stomach and its relationship with esophago-gastric adenocarcinoma. J Gastroenterol (2005) 0.85
Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol (2005) 0.85
Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and meal-stimulated plasma gastrin release in the absence of peptic ulcer disease. Am J Gastroenterol (1998) 0.84
The role of Acid in functional dyspepsia. Am J Gastroenterol (2011) 0.84
Long-term strict monitoring of plasma ghrelin and other serological markers of gastric diseases after Helicobacter pylori eradication. Hepatogastroenterology (2005) 0.83
Helicobacter pylori and microcirculation. Microcirculation (2009) 0.82
Ghrelin Levels in Gastric Mucosa before and after Eradication of Helicobacter pylori. Gut Liver (2007) 0.82
Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". Arch Intern Med (2011) 0.81
Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion. Am J Physiol Gastrointest Liver Physiol (2011) 0.79
Effects of Helicobacter pylori eradication therapy on gastric emptying measured using the 13C-octanoic acid breath test and the acetaminophen method. J Gastroenterol Hepatol (2006) 0.78
Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol (2011) 0.77
[Short version of the S3 (level 3) guideline "Helicobacter pylori and gastroduodenal ulcer disease" from the German Society for Digestive and Metabolic Diseases]. Dtsch Med Wochenschr (2009) 0.76
Dyspepsia. Curr Opin Gastroenterol (2012) 0.76
Eradication of Helicobacter pylori and gastrin-somatostatin link in duodenal ulcer patients. J Physiol Pharmacol (1996) 0.76
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Ulcerative colitis. BMJ (2013) 1.76
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol (2005) 1.59
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev (2015) 1.58
Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 1.57
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol (2008) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol (2005) 1.40
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol (2005) 1.28
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol (2005) 1.17
Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol (2009) 1.16
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol (2003) 1.12
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol (2007) 1.11
Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials (2012) 1.10
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08
Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol (2007) 1.07
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. Gut (2013) 1.05
Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol (2008) 1.04
A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology (2005) 1.02
Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol (2012) 1.02
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2013) 1.01
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol (2008) 0.97
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.96
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol (2009) 0.95
Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. Trials (2013) 0.93
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.93
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis (2010) 0.93
Does long term aspirin prevent cancer? BMJ (2010) 0.91
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol (2015) 0.89
Stress ulcer prophylaxis in critically ill patients: review of the evidence. Pol Arch Med Wewn (2012) 0.89
Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol (2009) 0.89
A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol (2004) 0.89
Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol (2007) 0.87
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 0.86
Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev (2012) 0.85
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
WITHDRAWN: Initial management strategies for dyspepsia. Cochrane Database Syst Rev (2009) 0.84
Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ (2013) 0.84
Eradicating H pylori. BMJ (2004) 0.83
Colorectal cancer screening with fecal occult blood testing (FOBT): an international perspective. Am J Gastroenterol (2006) 0.83
Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83
Managing dyspepsia. Curr Gastroenterol Rep (2009) 0.83
Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol (2009) 0.83
Current guidelines for dyspepsia management. Dig Dis (2008) 0.82
Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol (2014) 0.82
Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med (2009) 0.82
WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev (2010) 0.80
Barrett's esophagus and obesity: the missing part of the puzzle. Am J Gastroenterol (2008) 0.80
Non-erosive reflux disease--defining the entity and delineating the management. Digestion (2008) 0.80
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med (2010) 0.79
Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol (2009) 0.78
Does aspirin really reduce the risk of colon cancer? Lancet (2012) 0.78
The promises and perils of nurse-led flexible sigmoidoscopy screening. Can J Gastroenterol (2007) 0.78
Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed (2006) 0.78
A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making (2007) 0.78
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2009) 0.78
A glossary of economic terms. Eur J Gastroenterol Hepatol (2004) 0.78
Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn (2009) 0.78
Dyspepsia. BMJ (2013) 0.77
Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed (2006) 0.77